{
    "2019-07-29": [
        [
            {
                "time": "2019-07-30",
                "original_text": "Pre-Market Earnings Report for July 30, 2019: PG, MA, PFE, MRK, LLY, MO, COP, ECL, MMC, HCA, ETN, PEG",
                "features": {
                    "keywords": [
                        "Earnings",
                        "Pre-Market",
                        "PFE",
                        "MRK",
                        "LLY"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "consumer goods"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-30",
                "original_text": "Pfizer to Combine Off-Patent Drug Business With Mylan",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Mylan",
                        "Off-Patent",
                        "Drug",
                        "Business"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-30",
                "original_text": "Q2 Earnings Preview For Eli Lilly",
                "features": {
                    "keywords": [
                        "Q2",
                        "Earnings",
                        "Preview",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-30",
                "original_text": "Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up",
                "features": {
                    "keywords": [
                        "Sanofi",
                        "Q2",
                        "Earnings",
                        "Dupixent",
                        "EPS"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-30",
                "original_text": "Should You Buy Eli Lilly (LLY) Ahead of Earnings?",
                "features": {
                    "keywords": [
                        "Buy",
                        "Eli Lilly",
                        "Earnings"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-07-30",
                "original_text": "What's in Store for Array BioPharma (ARRY) in Q4 Earnings?",
                "features": {
                    "keywords": [
                        "Array BioPharma",
                        "Q4",
                        "Earnings"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-30",
                "original_text": "Is Eli Lilly (NYSE:LLY) A Risky Investment?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Risky",
                        "Investment"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}